The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

As of July 18, 2025, the Food and Drug Administration (FDA) said it has received three reports of fatal acute liver failure ...

The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute ...

This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

Sarepta Therapeutics Inc. made known a third gene therapy death, this time with SRP-9004 for limb-girdle muscular dystrophy. The patient was a late-stage, non-ambulatory 51-year-old man participating ...

Researchers have developed a new and improved viral vector -- a virus-based vehicle that delivers therapeutic genes -- for use in gene therapy for sickle cell disease. In advanced lab tests using ...

Swiss-based DiNAQOR has developed a revolutionary gene therapy platform which combines gene-vector-promoter constructs with loco-regional delivery to the heart for the treatment of cardiovascular ...

Gene therapies treat or prevent disease by tweaking the content or expression of cells' DNA. ... Other COVID-19 shots include the viral vector vaccines made by AstraZeneca and Johnson & Johnson, ...

Lentigen’s lentiviral gene therapy assets were acquired by German company Miltenyi Biotec in 2014. “Now is the perfect time to launch our business,” Dropulić said in a prepared statement.

AMSTERDAM--(BUSINESS WIRE)--VectorY, a fully integrated gene therapy company focused on the development of innovative vectorized antibodies for muscular and neurodegenerative disorders, today ...